LAEKFLAEKNA INC.

About LAEKNA INC. (LAEKF)

LAEKNA INC. (LAEKF) is a N/A company headquartered in Shanghai, China whose shares trade over-the-counter on the Pink tier.

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, and LAE120 for the treatment of cancer; LAE103 and LAE123 to treat muscle atrophy diseases; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis. The company has a collaboration with Eli Lilly and Company for the development of LAE102.

LAEKF key facts

Ticker symbol

LAEKF

Market tier

Pink

Headquarters

Shanghai, China

Estimated market cap

$2.60B (as of May 12, 2025)

Shares outstanding

355,981,000

Reporting standard

International Reporting: Hong Kong Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Explore more: Pink stocks · OTC stocks starting with L